Sertraline for the Treatment of Major Depressive Disorder in the US: Effectiveness and Acceptability in Real-World Practice.

Saved in:
Bibliographic Details
Title: Sertraline for the Treatment of Major Depressive Disorder in the US: Effectiveness and Acceptability in Real-World Practice.
Authors: Correll CU; Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.; Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.; Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA.; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany.; German Center for Mental Health (DZPG), Partner Site Berlin, Berlin, Germany.; Einstein Center for Population Diversity (ECPD), Berlin, Germany., Purushottamahanti P; Global Medical Affairs, Viatris Inc., Bangalore, India., Subramaniam K; Global Medical Affairs, Viatris Inc., Auckland, New Zealand., Bayan B; Real World Data and Analytics, Viatris Inc., Bangalore, India., Cook JP; Real World Data and Analytics, Viatris Inc., Canonsburg, PA, USA., Palmer EOC; Real World Evidence, Holmusk Technologies Inc., London, UK., Yeow J; Real World Evidence, Holmusk Technologies Inc., Singapore, Singapore., Lipunova N; Real World Evidence, Holmusk Technologies Inc., London, UK.
Source: Neuropsychiatric disease and treatment [Neuropsychiatr Dis Treat] 2026 Jan 15; Vol. 22, pp. 563433. Date of Electronic Publication: 2026 Jan 15 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101240304 Publication Model: eCollection Cited Medium: Print ISSN: 1176-6328 (Print) Linking ISSN: 11766328 NLM ISO Abbreviation: Neuropsychiatr Dis Treat Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1176-6328
DOI:10.2147/NDT.S563433